EquiManagement spotlights equine kidney disease

EquiManagement’s new Disease Du Jour episode on equine kidney disease puts a familiar but clinically tricky condition back in focus, with Dr. Thomas Divers walking through how acute and chronic renal disease present in horses and how they’re managed in practice. The discussion lands at a time when equine internal medicine has fresh consensus guidance aimed at standardizing how veterinarians recognize, classify, and treat kidney disease in horses. (horseradionetwork.com)

That context matters because equine kidney disease is often less straightforward than a single elevated chemistry value. The 2024 ECEIM consensus statement was developed to summarize evidence and expert experience on recognizing and managing kidney disease in horses. It emphasizes that azotemia has to be interpreted carefully, with clinicians distinguishing prerenal, renal, and postrenal causes, and recognizing that poor perfusion can progress into intrinsic kidney injury if not corrected. (pmc.ncbi.nlm.nih.gov)

One of the biggest challenges is early detection. According to the consensus statement, serum creatinine in horses typically does not rise above reference limits until glomerular filtration rate has been reduced by nearly 75%, meaning clinically important renal injury can be present before routine bloodwork looks dramatic. In chronic kidney disease, horses may show loss of body condition, mild to moderate polyuria and polydipsia, decreased performance, oral ulceration, or hypertension, while acute kidney injury may be tied to dehydration, sepsis, ischemia, anesthesia, or toxin exposure. (pmc.ncbi.nlm.nih.gov)

The consensus paper also sharpens the medication and management conversation. It lists aminoglycosides, oxytetracycline, bisphosphonates, and NSAIDs among nephrotoxic agents described in horses, with particular caution around phenylbutazone in at-risk patients. For acute kidney injury, intravenous fluid therapy is described as the therapeutic cornerstone to restore circulating volume, renal blood flow, and glomerular filtration. At the same time, the panel warns against overzealous fluid therapy, and notes that in stable chronic kidney disease with established polyuria, IV fluids may not be needed if the horse is drinking adequately. (pmc.ncbi.nlm.nih.gov)

Divers’ involvement also carries weight beyond a podcast appearance. He is a co-author on the ECEIM consensus statement and has separately reviewed acute kidney injury and renal failure in horses in Veterinary Clinics of North America: Equine Practice, underscoring that this is an area where expert opinion is being translated into more structured clinical guidance. That review and the consensus statement both reinforce a core point: acute kidney injury can be reversible, but only if it’s recognized and managed before persistent oliguria, anuria, or secondary complications narrow the horse’s options. (pubmed.ncbi.nlm.nih.gov)

Why it matters: For equine practitioners, this is less about a new therapeutic breakthrough than about better clinical discipline. Kidney disease in horses can be easy to underestimate early, especially when azotemia is attributed to dehydration alone or when subtle chronic signs are folded into aging or poor performance. The newer guidance suggests veterinarians should be especially alert in horses exposed to nephrotoxic drugs, systemic illness, or hypovolemia, and should pay close attention to urine output trends, hydration status, and serial creatinine values. Response within the first 24 to 72 hours matters: the consensus panel says falling creatinine and adequate urine production are more useful prognostically than a single severe value in isolation. (pmc.ncbi.nlm.nih.gov)

The broader industry takeaway is that equine renal care is moving toward more standardized decision-making, even if evidence gaps remain. The consensus authors note that some newer biomarkers, including SDMA, haven’t yet shown clear superiority over creatinine in horses, which leaves clinicians relying heavily on careful history, serial monitoring, urinalysis, and case-by-case judgment. That makes education-focused coverage like this episode useful: it helps translate a dense evidence base into practical reminders for field and hospital veterinarians. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase to watch is whether consensus recommendations lead to wider use of structured AKI risk assessment, earlier monitoring around nephrotoxic drugs, and more research on equine-specific biomarkers and staging tools that can catch disease before renal compromise becomes advanced. (pmc.ncbi.nlm.nih.gov)